⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Global Aplastic Anemia Industry Trends and Growth Outlook 2025-2035 Featuring Profiles of Pfizer, Novartis, and Sanofi
globenewswire.com
PFE
NVS
SNY
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
globenewswire.com
AMGN
CSL
NVS
REGN
SNY
UCB
AZN
IONS
TEVA
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
prnewswire.com
NVS
BOC Group Named a Challenger in the 2026 Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms
prnewswire.com
CSCO
NVS
BOC Group Named a Challenger in the 2026 Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms
prnewswire.com
CSCO
NVS
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
globenewswire.com
INBX
LLY
PFE
NVS
BMY
EXEL
JNJ
AZN
JAZZ
TLRY
THE SKIN OF COLOR SOCIETY (SOCS) UNITES 21 GLOBAL ORGANIZATIONS TO ADVANCE SKIN OF COLOR DERMATOLOGY
prnewswire.com
NVS
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
globenewswire.com
NVS
Paralyzed Veterans of America Takes 2026 Healthcare Summit + Expo to Vegas to Advance Care for Spinal Cord Injury, MS, and ALS
prnewswire.com
BIIB
NVS
Specialty Pharmaceuticals Market (2026-2031) - Rising Prevalence of Chronic and Rare Diseases Drives Growth
globenewswire.com
ABBV
AMGN
AZN
BIIB
BMRA
BMY
JNJ
MRK
NVS
PFE
REGN
SNY
TEVA
VRTX